Essential Tremor Device 🚀 FDA-Cleared Wearable by Encora
Discover Encora Therapeutics’ FDA-cleared essential tremor device—wearable neuromodulation with proven vibration trials. Learn how it can help.
From MIT Class Project to an FDA-Cleared Tremor Device
In 2017, an MIT student team hauled a rough wrist-worn prototype onto the stage at Kresge Auditorium - more box than product, with wires and a Raspberry Pi doing most of the heavy lifting. Then Michael, who'd been dealing with severe hand tremors, switched it on. The tremor eased enough for him to draw a spiral with noticeably better control. The room reacted right away. So did one practical question the students couldn't answer yet: when could other people get one?
The short version: it took nine years of revisions, clinical work, and a shift in the specific condition the company set out to treat. That project became Encora Therapeutics, and in February 2026 the US Food and Drug Administration cleared its wrist-based device to help adults with essential tremor.
This isn't just a feel-good "classroom to company" story. It's a look at what medical technology has to do beyond demos - figuring out who it's for, testing whether the effects hold up, navigating regulation, and planning for real-world use instead of a trial setting. Here's how Encora's approach works, what its clinical results support (and what they don't), and what to watch as the company looks toward wider access.
How an MIT Prototype Became a Company
Encora started in MIT's 2.009, Product Engineering Processes, a course focused on designing and presenting products. In 2017, students were asked to generate a large pool of ideas and then pick one to develop. Daniel Carballo proposed a wearable device that would use mechanical vibration to influence the body's movement-control system and reduce tremors.
At that point, it was far from a medical product. Carballo says the team was chosen despite his own doubts about whether it could actually work within a single semester. The group also lagged behind other teams at several milestones. But in the final week, they met Michael - someone whose early-onset Parkinson's made everyday tasks like using a drill, turning a screwdriver, and even filling out paperwork genuinely difficult.
The prototype was basic. Still, when Michael tried it, his tremor visibly decreased. He came back for the team's final presentation, and his demonstration - and his description of what changed for him - landed well with the audience. People wanted to know where they could buy something similar for relatives dealing with tremors. The students had one prototype, not a device they could sell.
That gap matters. A convincing demonstration can show an idea is worth investigating, but it doesn't prove the device will work reliably across a larger group, can be manufactured consistently, or is safe and practical for someone to use at home. The team had to take that early signal and turn it into a development program.
From coursework to product development
Some of the students kept working on the project after the class. They leaned on MIT resources such as MIT Sandbox, MIT FUSE, and the MIT Venture Mentoring Service as they explored commercialization. The team formed Encora Therapeutics in 2020. Three of the founders are still with the company: Carballo, Allison Davanzo, and Kyle Pina.
Moving from class to company didn't remove the uncertainty - it reshaped it. A prototype that works for one person on stage is not the same thing as a wearable people can use day after day. The hardware still needed development, and the team needed answers about which patients might benefit, how to test that benefit, and what evidence regulators would expect.
Encora initially focused on Parkinson's disease. In 2022, it ran a clinical trial with 20 Parkinson's patients in collaboration with Mass General Brigham. During development, the team concluded that essential tremor represented a more clear unmet need. Carballo has described it this way: Parkinson's has attracted more drug development activity, while essential tremor hasn't seen the same level of innovation.
That shift wasn't just academic - it shaped the product. A technology may begin with one condition, but the best first market depends on factors like how many people are affected, what treatments already exist, what clinical evidence can realistically be gathered, and how the intended use can be defined. The FDA clearance here is for adults with essential tremor - not a blanket clearance for every tremor disorder or for Parkinson's disease.
How the Wrist Device Is Designed to Reduce Tremor
Encora's device looks like a watch and delivers mechanical vibration at the wrist. The idea is that sensory information from the wrist can influence the signals involved in coordinating movement.
The body relies on sensory receptors to help determine where a limb is in space. As Carballo explains, vibration stimulates stretch receptors in the wrist. Those receptors send patterned signals through peripheral nerves and into the nervous system, reaching brain regions involved in interpreting sensory input and coordinating movement. The goal is to affect the neural activity associated with tremor - without surgically implanting electrodes.
In practice, it's wearable neuromodulation: stimulating the nervous system from outside the body. In Encora's case, the stimulus is mechanical, not implanted electrical stimulation. It's also worth saying what it isn't. This isn't about physically restraining the hand. It's about sensory stimulation changing how the nervous system contributes to tremor.
Why a vibration-based approach is different
Some severe tremor treatments involve surgery. Encora describes an alternative approach that includes drilling into the skull and placing electrodes to deliver electrical patterns in targeted brain regions. That's a very different level of intervention from a wrist device. They shouldn't be treated as interchangeable, because the mechanisms, risks, and clinical context are different.
A wrist-based design offers a non-invasive way to deliver stimulation. That doesn't automatically make it right for every patient, and it doesn't guarantee it will outperform medication, surgery, or other care. What it does allow is a testable, wearable intervention - without the surgical procedure required for implanted stimulation.
There's also a difference between making sense of a mechanism and proving clinical outcomes. A plausible biological explanation can help clarify how the design might work, but patients and clinicians still need evidence that people actually experience meaningful benefit - consistently - and that it fits into daily life. That's why the clinical studies matter so much here: they're not optional footnotes after the engineering is finished.
A device is a system, not just a vibration motor
A medical wearable has to work as a complete product. The stimulation needs to be delivered in a controlled way, and the device has to be comfortable and practical enough for real use. The source says patients have used Encora's device for 12 to 14 hours a day, suggesting some users wear it for large parts of the day. That's not a blanket instruction - people should follow the device's instructions and clinician guidance.
For a company, that translates into real engineering and operational work: refining the hardware, making production repeatable, supporting users, and keeping product claims consistent with the evidence and the regulatory clearance. A prototype can win applause. A product has to perform reliably outside the auditorium.
What the Clinical Trials and FDA Clearance Mean
Encora reports two later studies focused on essential tremor. In 2024, it ran a randomized controlled trial with 47 patients. In 2025, it conducted a 59-person home-use study in which patients used the device outside the clinic. The company reports that more than 70% of patients in both studies experienced meaningful improvement. In the home-use study, 78% of patients reported benefits after 90 days.
Those results are promising - especially since the later study involved home use rather than only a controlled demonstration setting. But it's still important to read the details carefully. These are reported outcomes from the studies, not proof that every person with essential tremor will benefit, and not evidence that tremor is eliminated or that this replaces all other treatment options.
The source summary doesn't include the full protocols, the specific outcome measures, the comparison results, or adverse-event reporting. Those details are exactly what help determine the size and practical meaning of the effect. Anyone weighing treatment should look at the device's labeling and talk through individual circumstances with a qualified healthcare professional.
What 510(k) clearance tells you
In February 2026, the FDA granted the device 510(k) clearance for use as a medical device to help adults with essential tremor. The terminology matters: this is cleared, not described in the source as FDA-approved.
A 510(k) clearance is a regulatory pathway based on showing a device is substantially equivalent to a legally marketed predicate device for its intended use. It's not a blanket statement that every claim is endorsed, and it doesn't mean the product is a cure. The scope is tied to the device's intended use and the supporting evidence included in the submission.
For readers, the practical takeaway is straightforward: FDA clearance is a meaningful step toward commercialization for the cleared use, but it isn't a guarantee that any given patient will benefit - or that insurance coverage is automatic. Clearance also doesn't extend to Parkinson's disease just because the MIT project was inspired by a person with Parkinson's. Encora says it hopes to explore that original mission further, but that's separate from the essential-tremor clearance discussed here.
How to assess the evidence without overreading it
When you see a medical device headline, try separating four questions:
- Who was studied? These later trials involved people with essential tremor. Results may not apply to other diagnoses.
- What outcome was measured? "Meaningful improvement" and patient-reported benefit can be useful, but the exact measures and study design affect how you interpret them.
- Where was it used? A home-use study adds real-world context, though it doesn't answer every question about long-term use or how it compares to other options.
- What is the device cleared to do? The clearance is to help adults with essential tremor. Broader applications would be future possibilities, not established current use.
None of this dismisses the promise. It just keeps the claims aligned with what the evidence actually supports. That matters even more for a product with a memorable origin story - because a strong demo can explain why the team kept going, while careful clinical evaluation helps determine where the device belongs in care.
What Comes Next for Patients and the Technology
FDA clearance is a milestone, not the end of commercialization. Encora says it's now focused on building a national sales force and seeking insurance coverage. It's also ramping up production so eligible patients can access the device. The source doesn't include a full launch timeline, pricing, or coverage details, so people should confirm availability and out-of-pocket costs directly with the company and a healthcare provider.
These next steps can be less visible than clinical results, but they determine whether a cleared device turns into something patients can realistically use. Production has to scale without damaging quality. Clinicians and patients need clear instructions. Insurers have to decide on coverage. And the company has to support people using the device outside a trial environment.
What patients should ask before considering a device
If you (or someone you care for) has essential tremor, the most useful next step is a clinical conversation - not a decision based on a headline. Consider asking a clinician:
- Does the device's cleared intended use match my diagnosis and needs?
- How might it fit alongside my current treatment plan?
- What benefits and limitations should I realistically expect?
- What usage instructions, precautions, or follow-up requirements should I know about?
- Is the device available where I live, and what would insurance or out-of-pocket costs look like?
These questions keep the discussion anchored in the individual. Essential tremor varies a lot in how it affects people, and a wearable option may or may not be a good fit depending on symptoms, daily activities, personal preferences, and existing care.
The broader opportunity - and the limit of the platform claim
Encora describes its approach as a potential platform for wearable neuromodulation. Carballo points to neurological movement disorders and other diseases as possible directions for future work. That's a reasonable research direction - but it's also important to separate a "platform" idea from proven treatments.
Each new condition would still require its own development work: defining the patient population, establishing a plausible mechanism, running appropriate clinical evidence, and receiving regulatory authorization for the intended use. A device that helps some adults with essential tremor can't be assumed to help people with Parkinson's or unrelated conditions. The opportunity could be broad, but the evidence remains specific to each condition.
For the technology sector, this is a useful reminder. A product can start with a compelling technical concept and a large theoretical market - but lasting value depends on repeatable outcomes in a clearly defined use case. Encora's progress came through narrowing focus, running studies, and seeking clearance for a specific patient group - not through claiming the wristband could solve every movement disorder from day one.
Conclusion
Encora's wrist device started as an odd-but-interesting idea in a product-design class and then went through the tougher steps that separate a prototype from a real medical product: iteration, clinical testing, regulatory review, and preparation for production. The FDA clearance gives adults with essential tremor a new option to discuss with their healthcare team, and the trial results suggest a potentially meaningful benefit - though it won't apply to everyone.
The real next test is operational: whether Encora can make the device available at scale, support patients, and build an evidence base that stays specific about what the product can do. If you're considering it, start with your clinician and confirm the current clearance, availability, and coverage details. For the original account of the project, see MIT's report on Encora Therapeutics.